Proteona co-founder publishes novel AI method for single cell data annotation
Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology
SINGAPORE, 5 November 2019 - Dr. Shawn Hoon, a scientific co-founder of Proteona, has published a novel AI method for single cell analysis data annotation. The article, titled “MapCell: Learning a comparative cell type distance metric with Siamese neural nets with applications towards cell-types identification across experimental datasets”, has been published on bioRxiv on 4 November 2019.
Read the full publication here.
For media queries, please contact:
Dr. Andreas Schmidt
Proteona is a precision medicine company in Singapore, Germany, and the US that is pioneering the use of single cell multi-omics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona enables pharmaceutical companies, biotech partners, and clinicians to integrate single cell level precision into their clinical projects. Proteona continues to develop comprehensive, disease-specific single cell databases combining gene expression, protein expression, and mutation information derived from each individual cells as well as drug response data for each sample. Proteona has been selected as a “One to Watch” by Nature Research Spinoff Award and a Winner of Falling Walls Ventures Breakthrough of the Year 2020. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR).